NGL Fine-Chem Full Year 2024 Earnings: EPS: ₹66.88 (vs ₹33.18 in FY 2023)
NGL Fine-Chem (NSE:NGLFINE) Full Year 2024 Results
Key Financial Results
- Revenue: ₹3.39b (up 22% from FY 2023).
- Net income: ₹413.2m (up 102% from FY 2023).
- Profit margin: 12% (up from 7.4% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: ₹66.88 (up from ₹33.18 in FY 2023).
NGLFINE Post-Clinical Trial Products
- Launched (during full year): 6.
All figures shown in the chart above are for the trailing 12 month (TTM) period
The primary driver behind last 12 months revenue was the Asia Pacific segment contributing a total revenue of ₹980.0m (29% of total revenue). Explore how NGLFINE's revenue and expenses shape its earnings.
NGL Fine-Chem shares are down 4.5% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for NGL Fine-Chem that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if NGL Fine-Chem might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:NGLFINE
NGL Fine-Chem
Manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally.
Excellent balance sheet with slight risk.
Market Insights
Community Narratives


Recently Updated Narratives
Constellation Energy Dividends and Growth
CoreWeave's Revenue Expected to Rocket 77.88% in 5-Year Forecast
Bisalloy Steel Group will shine with a projected profit margin increase of 12.8%
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
